CAR-NK的构建策略及在血液系统肿瘤中的研究进展

The construction strategy of CAR-NK and its research progress in hematological tumors

自然杀伤(natural killer cells,NK)细胞是先天免疫系统不可或缺的一部分,为抵御异常细胞攻击人体提供了第一道屏障。嵌合抗原受体T细胞(CAR-T)工程是近年来癌症免疫治疗领域的研讨热点,它改变了血液肿瘤的传统治疗方法,这种新颖的治疗方式已经在血液肿瘤中显示出了令人振奋的结果。然而,CAR-T的临床应用受到了高昂的制造成本和各种副作用的限制。NK细胞由于具有更好的安全性、“现成”生产的可行性和强大的细胞毒性激发了人们开发用于癌症治疗的CAR工程NK细胞(CAR-NK)的兴趣,CAR-NK有望取代CAR-T成为更有前景的抗癌方法。本文中我们描述了当前CAR-NK的构建策略和在血液系统肿瘤中的研究进展。

Natural killer(NK)cells are an indispensable part of the innate immune system and provide the first barrier against abnormal cells attacking the human body.Chimeric antigen receptor T cell(CAR-T)engineering has been a research hotspot in the field of cancer immunotherapy in recent years,it has changed the traditional treatment methods of hematological tumors.This novel treatment method has shown exciting results in hematological tumors.However,the clinical use of CAR-T has been limited by high manufacturing costs and various side effects.NK cells have better safety,"ready-made"production feasibility and strong cytotoxicity have stimulated people’s interest in the development of CAR-engineered NK cells(CAR-NK)for cancer treatment,CAR-NK is expected to replace CAR-T becomes a more promising anti-cancer method.In this review,we describe the current CAR-NK construction strategy and the research progress in hematological tumors.